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A phase 2 evaluation of live attenuated parainfluenza type 3 (PIV3)–cold passage mutant 45 (cp45) vaccine
was conducted in 380 children 6–18 months old; 226 children (59%) were seronegative for PIV3. Of the 226
seronegative children, 114 received PIV3-cp45 vaccine, and 112 received placebo. No significant difference in
the occurrence of adverse events (i.e., runny nose, cough, or temperature 38C) was noted during the 14
days after vaccination. There was no difference between groups in the occurrence of acute otitis media or
serous otitis media. Paired serum samples were available for 109 of the seronegative vaccine recipients and
for 110 of the seronegative placebo recipients; 84% of seronegative vaccine recipients developed a 4-fold
increase in antibody titers. The geometric mean antibody titer after vaccination was 1:25 in the vaccine group
and !1:4 in the placebo group. PIV3-cp45 vaccine was safe and immunogenic in seronegative children and
should be evaluated for efficacy in a phase 3 field trial.
Human parainfluenza viruses (PIVs) are important
causes of serious respiratory tract disease in infants and
young children. According to the US Institute of Med-
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icine, 25% of children !5 years old experience a clin-
ically significant PIV infection annually, and ∼2% of
PIV-infected infants will require hospitalization [1].
Four types of PIV are associated with respiratory illness
in young infants and children. Of special significance
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is PIV type 3 (PIV3), which causes pneumonia and bronchiolitis
and ranks second only to respiratory syncytial virus (RSV) as
a cause of bronchiolitis and pneumonia in infants !6 months
old [2–4]. PIV3 can cause severe disease throughout the first
2 years of life, and virtually all children have experienced pri-
mary PIV3 infections by age 3–4 years. Overall, PIV3 is con-
sidered to be responsible for ∼11% of hospitalizations for pe-
diatric respiratory tract disease in the United States [1].
Past attempts to develop inactivated PIV3 vaccines showed
that resistance to disease was not induced, despite the devel-
opment of serum antibodies after vaccination [5]. Protection
against PIV3 in humans is most likely to be achieved by the
induction of both circulating and mucosal antibodies that are
active against the hemagglutinin-neuraminidase (HN) glyco-
protein (the attachment protein) and the fusion glycoprotein,
2 surface antigens that induce protective neutralizing antibodies
[6, 7]. Such protective mucosal and circulating antibodies
should be induced most efficiently by delivery of a live atten-
uated virus vaccine to the mucosa of the respiratory tract [8].
The live attenuated virus vaccine evaluated in the present
study, JS strain, was derived from human wild-type PIV3 that
was originally isolated from a 1-year-old child with a febrile
respiratory illness [9–11]. Several attenuated mutants of the JS
strain were derived by passaging the virus numerous times in
primary monkey kidney cells at sequentially lower temperatures
that are suboptimal for PIV3 replication. After 12, 18, and 45
cold passages, mutants cp12, cp18, and cp45, respectively, were
isolated and characterized. During the process of low-temper-
ature passage, each of the mutants acquired 3 phenotypic mark-
ers: cold adaptation (ca; the ability to replicate efficiently in vitro
at the suboptimal temperature of 20C), temperature sensitivity
(ts; restricted growth at 39C in tissue culture), and attenuation,
manifested by restricted replication in hamsters and chimpan-
zees, compared with that of wild-type virus [9–12].
Phase 1 studies of PIV3-cp45 vaccine, which was produced
in fetal rhesus monkey lung (FRhL-2) tissue culture cells, have
been conducted in seropositive children 6 months to 10 years
old, seronegative infants 6–36 months old, and infants 1–2
months old [13, 14]. In general, the vaccine appeared to be
satisfactorily attenuated, infectious, immunogenic, and phe-
notypically stable. However, because PIV3-cp45 replicates to
modest titers on monolayer cultures of FRhL-2 cells, produc-
tion of vaccine virus in this cell line would be inefficient for
larger-scale manufacturing; thus, an easily scalable and cost-
effective production process for PIV3 that propagates the virus
in Vero cells grown on microcarrier beads in a bioreactor was
developed by Wyeth Vaccines Research (Pearl River, NY).
In phase 1 studies, PIV3-cp45 grown in Vero tissue culture
was generally well tolerated by all cohorts, with the exception
that, in the seronegative cohort, otitis media (OM) was ob-
served in 3 of 32 vaccine recipients and in none of 14 placebo
recipients [15]. Interpretation of the significance of this finding
was uncertain because of the frequent acquisition of other in-
tercurrent viral infections. The overall rates of upper respira-
tory–tract illness (URI) were very similar in the vaccine and
placebo groups, and PIV3 isolates recovered from these children
retained the ts phenotype [15]. Thus, as with PIV3-cp45 grown
in FRhL, the vaccine virus grown in Vero tissue culture appeared
to be satisfactorily attenuated, infectious, immunogenic, and phe-
notypically stable. We therefore undertook a phase 2 study of
PIV3-cp45 vaccine, to compare the safety profile of a dose of
105 pfu administered intranasally (inl) to children 6–18 months
old with that of placebo and to assess the immunogenicity of
the vaccine. The phase 2 study was sufficiently powered to eval-
uate the frequency of OM in vaccine and placebo groups.
SUBJECTS, MATERIALS, AND METHODS
Study design and vaccine. We enrolled ∼400 healthy sub-
jects 6–18 months old in a multicenter, double-blind, placebo-
controlled safety and immunogenicity trial. This sample size
was chosen to enroll ∼200 PIV-seronegative children. Eligible
subjects were assigned to receive the investigational study vac-
cine according to a randomization schedule generated by the
sponsor’s statistician and provided in sealed randomization en-
velopes to study personnel at each site responsible for preparing
study vaccine for administration. Each subject was randomized
to receive either a single dose of PIV3-cp45 at pfu or51 10
placebo (PBS with sucrose, phosphate, and glutamate) inl as
nose drops instilled while the subject was supine. Randomi-
zation was a 1:1 ratio of vaccine to placebo.
Subjects. Study subjects were healthy children 6–18
months old, whose parents or guardians gave written, informed
consent. The human-experimentation guidelines of the US De-
partment of Health and Human Services and those of the au-
thors’ institutions were followed in the conduct of this clinical
research. Each subject’s history was reviewed, and a physical
examination was performed to verify that the health and de-
velopment of all subjects were normal. Subjects with any of
the following conditions or characteristics were excluded from
study enrollment or from continued participation: immuno-
suppression or taking immunosuppressive medication; serious
chronic illness; cardiac or respiratory illness, including those
with 11 prior episode of wheezing (including illnesses diag-
nosed as asthma or reactive airway disease) confirmed by a
physician or subjects with pressure equalization tubes; members
of a household with a pregnant woman, an immunocompro-
mised individual, or an infant !6 months old; or attendance
at day care with infants !6 months old. Attendance at a day-
care facility in which children were separated by age was ac-
ceptable if the vaccine recipient did not spend any time in the
area designated for infants !6 months old and if conditions
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pertaining to any common area of the facility minimized op-
portunities for transmission of virus through direct physical
contact between children or by the aerosol route. Subjects with
self-limiting illnesses were included after the condition resolved
and if no other exclusion criteria were met. These exclusion
criteria included acute febrile illness (38C), acute OM (AOM),
receipt of short-term antibiotic therapy for acute illness, receipt
of any vaccine within the previous 2 weeks, receipt of any live
vaccine within the previous 4 weeks, or receipt of gamma glob-
ulin within the past 3 months. Infants born at !37 weeks of
gestation were deferred from study participation until they were
at least 1 year old. Children did not receive other vaccines for
42 days after enrollment.
Procedures. Serum samples were obtained before inl vac-
cination, to determine prevaccination antibody levels. Subjects
received either the vaccine or the placebo by nose drops in a
volume of 0.25 mL/nostril, for a total dose of 0.5 mL. Vacci-
nations were administered between 28 October 1998 and 13
November 2000, and vaccinations were not given during winter,
to reduce intercurrent wild-type viral infection. The parents
were asked to keep track of any illness or symptoms on a parent
diary card each day for 14 days after vaccination; electronic
thermometers were provided, and parents were asked to obtain
daily oral, rectal, or axillary temperatures. Parents were asked
to record the child’s temperature at bedtime daily for 14 days
after vaccination and whenever the child felt warm during the
42 days after vaccination. Children were seen by study person-
nel twice in the 2 weeks after vaccination (day 7 and 14, 1
day). These brief visits (20–30 min each) allowed the study staff
to examine the child closely for any signs of a runny nose, sore
throat, fever (temperature 38C), cough, respiratory illness,
or an ear infection. Study staff also contacted the parents by
telephone on days 21, 28, and 35 (2 days), to inquire if the
child had experienced any symptoms of illness. Six weeks after
the first vaccination visit, all enrolled children returned to the
clinic for a brief physical examination, and a blood sample was
obtained to measure the child’s antibody response to the
vaccination.
During the 42 days of the study, a clinician was available 24
h/day to examine ill children. An examination was performed
if a child had a rectal temperature 38C (or equivalent if oral
or axillary temperatures were taken), respiratory illness, or
symptoms suggestive of an ear infection. For all study sub-
jects, fever, URI (rhinorrhea or pharyngitis), cough, and lower
respiratory–tract illness (LRI) were defined as described else-
where [14]. During each illness, the child’s ears were examined
for signs of an ear infection, and a nasal-wash sample was
obtained for viral culture to determine whether there was an
intercurrent viral infection. Otoscopy was performed at each
clinic visit at which the child was well. AOM was defined as
an inflamed, immobile tympanic membrane, with or without
bulging, observed by a physician or nurse practitioner and con-
firmed by tympanometry or a second observer. These findings
were noted independently of fever or other respiratory symp-
toms. An abnormal tympanogram alone was not considered to
be diagnostic of AOM. Serous OM was defined as all other
cases of OM not fitting the above strict criteria. All children
were examined at the end of the study: day 42 (range, 35–66
days) after vaccination. Serum samples from all subjects were
tested for antibodies to PIV3 (Washington/57 strain) by the
hemagglutination inhibition (HAI) antibody test [13], starting
at a serum dilution of 1:4; children with a titer of 1:8 were
considered to be seronegative. Vaccine virus shedding was not
routinely determined in the present study, to avoid any con-
founding clinical findings that may be caused by the frequent
nasal-wash samples that are necessary to obtain samples for
viral cultures.
Statistics. The event of primary analysis was AOM in se-
ronegative subjects. It was estimated that ∼50% of the enrolled
subjects would be seronegative. This sample size was sufficient
to reject the hypothesis, with a power of 82%, that the rate of
OM in the vaccine group was 11% higher (90% confidence
interval, upper bound) than the rate of OM in the placebo
group, assuming that the placebo rate was 10%. For analysis
of possible adverse reactions to vaccination (i.e., runny nose,
cough, or fever) Fisher’s exact test P values were adjusted for
each symptom or sign or each day by Bonferroni’s method.
Fisher’s exact test was used to compare the occurrence of OM
in vaccine recipients and placebo recipients.
RESULTS
Enrollment. Three hundred eighty children were enrolled in
the study and were given either PIV3-cp45 vaccine or placebo
inl. Of those 380 children, 226 (59%) were seronegative (an-
tibody to PIV3 1:8 by HAI antibody test). Of the 226 se-
ronegative children, 114 received PIV3-cp45 vaccine, and 112
received placebo. Three hundred seventy-two (97.9%) com-
pleted the 42 days of study.
Signs and symptoms of respiratory disease. Figure 1A, 1B,
and 1C illustrates, in the seronegative cohort, the daily fre-
quency of runny nose, cough, or fever during the 14 days in
which parents recorded symptoms on diary cards. There was
no statistically significant difference between groups in the fre-
quency of runny nose, cough, or fever on any day. In both the
vaccine and placebo groups, children selected on day 0 at time
0 for the absence of runny nose, cough, or fever experienced
an increase in these events during the first days of the study.
This is most dramatically seen for the occurrence of runny nose
(figure 1A). Children with runny nose were excluded at entry,
and, therefore, the occurrence of runny nose increased during
the study in both the placebo and the vaccine recipients; this
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Figure 1. A, Percentage of parainfluenza virus 3 (PIV3)–seronegative children with runny nose on days 0–14 after intranasal (inl) vaccination with
PIV3–cold passage mutant 45 (cp45) (hatched bars) or placebo (white bars). No statistically significant differences between vaccine and placebo groups
occurred on any day ( , Fisher’s exact test with Bonferroni’s correction). B, Percentage of PIV3-seronegative children with cough on days 0–14P 1 .05
after inl vaccination with PIV3-cp45 (hatched bars) or placebo (white bars). No statistically significant differences between vaccine and placebo groups
occurred on any day ( , Fisher’s exact test with Bonferroni’s correction). C, Percentage of PIV3-seronegative children with fever (temperatureP 1 .05
38C) on days 0–14 after inl vaccination with PIV3-cp45 (hatched bars) or placebo (white bars). No statistically significant differences between
vaccine and placebo groups occurred on any day ( , Fisher’s exact test with Bonferroni’s correction).P 1 .05
illustrates the phenomenon of return to the mean, whereby, on
any given day, ∼20% of young children have runny nose, as
seen in other similar studies [16]. A similar phenomenon was
observed for cough and fever, with baseline occurrence of cough
in ∼10% of the children after day 7, and the baseline occurrence
of fever in ∼3%–6% of children, depending on the day ob-
served. Among the seropositive children, the frequency of signs
and symptoms of respiratory illness (including runny nose,
cough, or fever) was not significantly different on any day (data
not shown). There was no difference in the frequency of chil-
dren with findings of LRI (9/189 in the vaccine group vs. 12/
191 in the placebo group; , Fisher’s exact test).Pp .65
Isolation of viruses during illness episodes. In the present
study, nasal-wash samples were obtained only during illness
visits. A total of 19 vaccine virus isolates were recovered from
the nasal-wash samples of 17 (9.0%) of 189 vaccine recipients
during these unscheduled visits. The majority of the isolates
(17/19 [89.5%]) were recovered from seronegative subjects (ta-
466 • JID 2004:189 (1 February) • Belshe et al.
Table 1. Isolation of vaccine and wild-type parainfluenza














Vaccinelikea 15 0 17b 0
Wild type 0 2 1b 2
Days 12–22
Vaccinelike 1 0 1 0
Wild type 1 1 1 1
Days 23
Vaccinelike 0 0 0 0
Wild type 2 4 2 5
Any day
Vaccinelike 16 0 17b 0
Wild type 3 7 4b 8
NOTE. Data are no. of subjects shedding the indicated virus. cp45,
Cold passage mutant 45.
a Temperature-sensitive and cold-adapted phenotypes.
b Three subjects who shed PIV3 (subject 1024 shed vaccine virus, sub-
ject 1829 shed wild-type virus, and subject 1828 shed both strains) were
placed in the “all” category because their pretreatment blood samples
were either unavailable (1829) or were obtained too many days before
vaccination to assure a seronegative status at time of vaccination.
Table 2. Subjects experiencing acute otitis media in the







group % 90% CIaPIV3-cp45 Placebo
Seronegativeb
1–11 5 (4.4) 7 (6.3) 1.9 9.6 to 5.5
12–22 9 (7.9) 8 (7.1) 0.8 6.8 to 9.6
23–42 10 (8.8) 8 (7.1) 1.6 6.0 to 10.7
1–42 20 (17.5) 17 (15.2) 2.4 6.9 to 13.0
Any 21 (18.4) 18 (16.1) 2.3 7.1 to 13.1
Allc
1–11 10 (5.3) 10 (5.2) 0.1 5.2 to 5.4
12–22 16 (8.5) 13 (6.8) 1.7 4.2 to 7.7
23–42 20 (10.6) 12 (6.3) 4.3 1.7 to 10.5
1–42 38 (20.1) 26 (13.6) 6.5 0.8 to 14.0
Any 39 (20.6) 27 (14.1) 6.5 0.9 to 14.1
NOTE. Data are no. (%) of subjects, except where noted. PIV3-
cp45, parainfluenza virus 3–cold passage mutant 45.
a The 2-sided confidence intervals (CIs) were calculated by use of
StatXact (Cytel). 90% CIs represent the 90% CI for the percentage of
subjects in the PIV3-cp45 vaccine group with acute otitis media minus
the percentage of subjects in the placebo group and, in each case, in-
cludes 0%. The denominator is the no. of randomized subjects.
b In the seronegative cohort, 114 subjects received PIV3-cp45, and
112 subjects received placebo.
c In the “all” cohort, 189 subjects received PIV3-cp45, and 191 sub-
jects received placebo.
ble 1). All vaccine isolates were recovered within the first 14
days after vaccination. Both vaccine and wild-type PIV3 was
detected in the nasal-wash sample of 1 subject during an illness
visit. Three subjects who shed PIV3 (1 vaccine, 1 wild type,
and 1 both strains) were placed in the “all” category because
their pretreatment blood sample was either unavailable (np
) or was collected too long before vaccination ( ) to1 np 2
assure a seronegative status at time of vaccination.
To determine whether the higher proportion of vaccine iso-
lates recovered from seronegative subjects was due to this co-
hort’s lack of preexisting antibody to PIV3 or to more-frequent
sampling of these subjects, nasal-wash sample collection rates
among seronegative and seropositive subjects were compared
and were found to be statistically similar ( ). Overall, 137P 1 .90
(60.6%) of 226 seronegative subjects and 95 (61.7%) of 154 se-
ropositive subjects enrolled in the study had at least 1 nasal-
wash sample obtained after vaccination. Within the first 11 days
after vaccination, the nasal-wash sample collection rates were
also similar between cohorts, with 71 (31.4%) of 226 seronegative
subjects and 42 (27.3%) of 154 seropositive subjects having at
least 1 nasal-wash sample obtained. Wild-type PIV3 was isolated
from 4 (2.1%) of 189 vaccine recipients and 8 (4.2%) of 191
placebo recipients in the study ( , Fisher’s exact test).Pp .38
Children enrolled in the present study experienced inter-
current infections with respiratory pathogens other than PIV3.
PIV1, PIV2, RSV, adenovirus, cytomegalovirus, enterovirus,
and rhinovirus were isolated from subjects enrolled in the pres-
ent study. With the exception of PIV3, the most commonly
recovered pathogens were RSV (2.6% of vaccine recipients and
1.6% of placebo recipients), adenovirus (1.1% of vaccine re-
cipients and 3.7% of placebo recipients), enterovirus (3.2% of
vaccine recipients and 2.1% of placebo recipients), and rhi-
novirus (1.1% of vaccine recipients and 2.1% of placebo re-
cipients). In general, these viruses were isolated from children
in both treatment groups throughout the entire study period,
with no temporal relationship to vaccination. Among the 9
(4.8%) vaccine recipients and 12 (6.3%) placebo recipients who
had evidence of LRI, viruses were recovered from 3 vaccine
recipients (1 isolate each of PIV2, RSV, and vaccine virus) and
from 5 placebo recipients (RSV, PIV3 [wild type, in 2 subjects],
PIV1, and rhinovirus).
AOM. The occurrence of AOM among the seronegative
subjects and among all subjects is summarized in table 2. The
occurrence of AOM was common in both the vaccine recipients
and placebo recipients and was divided into that occurring
during the early postvaccination interval (days 1–11, the period
of peak vaccine virus replication [13–15]), the interval when
most vaccine virus replication had waned to absent or low levels
(days 12–22), and the late postvaccination period, when the
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Table 3. Subjects experiencing either acute otitis media or
serous otitis media in the seronegative cohort and in all sub-






group % 90% CIaPIV3-cp45 Placebo
Seronegativeb
1–11 11 (9.6) 12 (10.7) 1.1 10.1 to 7.6
12–22 18 (15.8) 20 (17.9) 2.1 12.2 to 7.8
23–42 15 (13.2) 15 (13.4) 0.2 9.8 to 9.1
1–42 34 (29.8) 33 (29.5) 0.4 10.1 to 12.2
Any 35 (30.7) 34 (30.4) 0.3 10.2 to 12.2
Allc
1–11 19 (10.1) 20 (10.5) 0.4 7.3 to 5.6
12–22 28 (14.8) 32 (16.8) 1.9 9.7 to 4.9
23–42 28 (14.8) 27 (14.1) 0.7 6.4 to 7.9
1–42 56 (29.6) 53 (27.7) 1.9 6.4 to 10.3
Any 57 (30.2) 54 (28.3) 1.9 6.5 to 10.4
NOTE. Data are no. (%) of subjects, except where noted. PIV3-cp45,
parainfluenza virus 3–cold passage mutant 45.
a The 2-sided confidence intervals (CIs) were calculated by use of per-
centage of subjects in the placebo group and, in each case, includes 0%.
The denominator is the no. of randomized subjects.
b In the seronegative cohort, 114 subjects received PIV3-cp45, and 112
subjects received placebo.
c In the “all” cohort, 189 subjects received PIV3-cp45, and 191 subjects
received placebo.
viral cultures were generally negative for vaccine virus (days
23–42). There was no statistically significant difference between
groups in the frequency of AOM at any of these intervals nor
did the overall total number of AOM cases differ between
groups. The occurrence of all OM, defined as any evidence of
AOM or serous OM, is shown in table 3. There was no sig-
nificant difference between groups or among all subjects in the
occurrence of all OM, regardless of serostatus.
Immunogenicity. Paired serum samples were available for
109 of the seronegative vaccine recipients and for 110 of the
seronegative placebo recipients. The antibody response to PIV3
is summarized in figure 2 and table 4. Eighty-six of the sero-
negative vaccine recipients (79%) developed 4-fold increase
in antibody titer or seroconversion from 1:8 to 1:16. After
vaccination, the geometric mean antibody titer was 1:25 among
the vaccine recipients. In contrast, only 13 (12%) of 110 placebo
recipients had an antibody response after vaccination. These
13 children likely had intercurrent natural infection with wild-
type PIV3, which was circulating in the community at the time
of the study. Postvaccination geometric mean titer was !1:4 in
the placebo recipients. Among the seropositive subjects, pre-
vaccine antibody titer was 1:50 and did not increase after vac-
cination (figure 2B and table 4).
DISCUSSION
Previous clinical trials have confirmed the viral-shedding pat-
tern, genetic stability, and immunogenicity of Vero tissue cul-
ture–produced PIV3-cp45 vaccine in adults, children, and in-
fants [15]. A single dose of 106 pfu of PIV3-cp45 was evaluated
in adults and seropositive children, single doses of 104 or 105
pfu were evaluated in seronegative children, and 2 doses at 1-
or 3-month intervals were evaluated in infants 1–2 months old
[15]. Ninety-four percent of seronegative vaccinated children
and 94% of vaccinated infants were infected by the vaccine
virus after 1 dose. Signs and symptoms of mild respiratory
illness were common in both vaccine and placebo groups of
seronegative children and infants and occurred in up to one-
half of placebo recipients; OM was reported in 3 of 32 vacci-
nated children. These and other similar phase 1 studies have
been effective screening studies to eliminate insufficiently at-
tenuated or overly attenuated live attenuated vaccine candi-
dates, but phase 1 studies are limited in assessing with precision
the possible association of OM with vaccine because of study
size [15, 17]. The present phase 2 evaluation was specifically
undertaken to assess the frequency of common signs and symp-
toms of AOM and to obtain more-precise estimates of the
frequency of signs and symptoms of URI that might be caused
by vaccine virus replication.
The occurrence of runny nose and fever increased in both
the vaccine and placebo groups during the 7 days after vac-
cination. Children who were selected for enrollment were afe-
brile and did not exhibit runny nose or cough. The diary card
information recorded by parents noted that, later on the day
of vaccination, 11% of children who received vaccine and 13%
of children who received placebo exhibited runny nose. Cough
and fever were also present in some children on the day of
vaccination, but not more frequently in either group. On sub-
sequent days, the frequency of runny nose increased and peaked
on day 8 (34% in the placebo group and 28% in the vaccine
group) before returning to a level of 16%–18% on day 14, after
which data were not collected. We believe that this increase in
the frequency of runny nose is a result of the selection of
children on day 0 without manifestations of URI and that a
return to the mean baseline values of ∼20% of children with
runny nose accounts for much of this observation. Selection
of well children without symptoms of URI may result in the
selection of children who are susceptible to prevalent viruses
causing URI in the community, and the peak incidence of
symptoms of URI on day 8 may represent acquisition of these
agents by both the vaccine and placebo groups. In contrast to
live attenuated influenza vaccine, which is associated with a
slight increase in fever on day 2 after vaccination and runny
nose on days 2, 3, 7, and 8 after vaccination [16], an increase
in these minor events was not observed in the present study
of PIV3-cp45; these findings further indicate the highly atten-
Figure 2. A, Reverse cumulative distribution curves of serum hemagglutination inhibition (HAI) antibody titers to parainfluenza virus 3 (PIV3) in
seronegative children with paired serum samples available for analysis. Cumulative proportion of children achieving the indicated HAI titer is shown
before and after vaccination with PIV3–cold passage mutant 45 (cp45) or placebo. Among 109 seronegative vaccine recipients and 110 placebo
recipients, 86 (79%) and 13 (12%), respectively, had a 4-fold antibody increase ( , Fisher’s exact test). The postvaccine geometric mean antibodyP ! .001
titer was 1:25 for vaccine recipients and !1:4 for placebo recipients. , Before PIV3-cp45; , after PIV3-cp45; , before placebo; +, after placebo.
B, Reverse cumulative distribution curves of serum HAI antibody to PIV3 for seropositive subjects. Prevaccination GMT was 1:50 for both vaccine and
placebo groups and did not increase after vaccination. , PIV3-cp45; , placebo.
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Table 4. Serum hemagglutination inhibition (HAI) antibody response within 42 days (range, 35–56 days) after administration of
parainfluenza virus 3 (PIV3)–cold passage mutant 45 (cp45) vaccine or placebo intranasally, by prevaccine antibody status.
Prevaccine serum antibody status to PIV3


















Prevaccine Postvaccine Prevaccine Postvaccine
PIV3-cp45 109a 86 (79)b !1:4 1:25 60 2 (3) 1:50 1:46
Placebo 110 13 (12) !1:4 !1:4 60 0 (0) 1:50 1:44
NOTE. GMT, geometric mean titer.
a Nos. of subjects with paired serum samples available are reported.
b , vs. placebo (Fisher’s exact test).P ! .001
uated nature of this PIV3 vaccine. Vaccination did not appear
to confer significant protection against the causes of runny nose,
cough, or fever during the 14 days after vaccination. Vaccination
did not cause or protect against AOM or serous OM occurring
within 42 days of vaccination. This result does not mean that
the vaccine will not protect against PIV3-associated URI, LRI,
or OM; rather, the occurrence of these illnesses caused by wild-
type PIV3 during this short study was too infrequent to measure.
Phase 3 studies are needed to measure these potential vaccine
benefits.
PIV3-cp45 vaccine was immunogenic, and a single dose in-
duced HAI antibody in 79% of seronegative (HAI titer 1:8)
children. A single dose of vaccine increased serum PIV3 an-
tibody to within 2-fold of preexisting, naturally acquired an-
tibody titers observed in the seropositive subjects. In a previous
study of PIV3-seronegative children, 18 (90%) of 20 children
tested had 4-fold increases in HAI antibody titers, and 21
(100%) of 21 tested shed vaccine virus [15]. In contrast, se-
ropositive children (titer 1:16) or adults shed vaccine virus
less frequently than did seronegative children (2/16 [12%] se-
ropositive children and 2/20 [10%] adults shed virus) and did
not boost serum antibody titers (0/12 seropositive children and
0/10 adults had increases in antibody titers) [15]. Seropositive
children 6–18 months old did not have increases in serum
antibody titers in the present study. However, 2 doses of vaccine
might improve the proportion of seronegative children who
develop antibody after vaccination with PIV3-cp45.
In a previous study of this vaccine in infants 4–12 weeks old
[15], 31 (94%) of 33 infants shed vaccine virus after dose 1 of
PIV3-cp45 vaccine, but serum HAI antibody titers increased
in the presence of maternal antibody (prevaccine geometric
mean titer, 5.3 log2) in only 4 (13%) of 31 infants tested. A
second dose of PIV3-cp45 vaccine given 1 or 3 months later
resulted in vaccine virus shedding in 47% and 77% of infants,
respectively, and only 1 infant (3%) had an HAI antibody re-
sponse [15]. In contrast, IgA antibody to HN protein developed
in more than one-half of the vaccinated infants after dose 1,
and IgA levels were boosted in 47% and 66% of infants after
dose 2 at 1 or 3 month intervals, respectively. These results are
similar to the low frequency of serum antibody response ob-
served in infants who are vaccinated with live attenuated RSV
vaccines; multiple doses of live attenuated vaccine appear to
be needed when infants are vaccinated in the face of maternal
antibody and an immature immune system [17].
PIV3-cp45 vaccine is expected to prevent several significant
clinical syndromes commonly caused by PIV3, including AOM,
LRI, and febrile URI, but determination of efficacy will require
an extended period of surveillance because PIV3 infections oc-
cur throughout the year [2–4]. An inl vaccine schedule to pre-
vent LRI in infants, with vaccination at 1 month and again at
4 months, followed by inl boosting at 1 year, would be an
attractive vaccine schedule to evaluate for efficacy, considering
the results of the present phase 2 safety trial and those of the
previous phase 1 trial in infants [15]. The addition of live
attenuated RSV vaccine and, possibly, other live attenuated vac-
cines (PIV1, PIV2, and human metapneumovirus) would be a
significant advance in controlling viral respiratory disease in
young children, but these vaccines may not be available for
several years. The safety and immunogenicity of PIV3-cp45
indicate that this vaccine should be evaluated for efficacy and
effectiveness to help control this common cause of significant
respiratory disease and AOM in infants and young children.
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